The approval and success of powerful new cancer treatments such as CAR T-cell therapy are breeding optimism among companies, scientists and patients around the world.TD2 can help influence your trial design and get your drug on a faster path to approval.
September 30, 2020
- TD2 Routine Analysis and More
- Specimen Stability Considerations During Flow Cytometry Assay Development, Optimization and Validation
- Fluorescent Cell Barcoding Using Flow Cytometry For High Throughput Testing
- Flow Cytometry Processing and Analysis of Tumor Specimens: Testing Viability and Staining Post Shipping
- The Importance of Conducting PDX Oncology Studies in a Humanized Immune System
TD2 Routine Analysis and More
By Jennifer J. Stewart, PhD
Specimen Stability Considerations During Flow Cytometry Assay Development, Optimization and Validation
By Jennifer J. Stewart, PhD
Fluorescent Cell Barcoding Using Flow Cytometry For High Throughput Testing
By Rubina Pal, PhD, Flow Cytometry Scientist
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
